Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
cAMeLot-2
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- NCT06852222 ↗
- Recruiting
- Janssen Research & Development, LLC
- Focused
We haven't built an HCP commentary report on cAMeLot-2 (bleximenib) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on cAMeLot-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 2 | |
| X threads | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Bleximenib; Venetoclax (VEN); Azacitidine (AZA); Placebo
- Arms
- Arm A: Bleximenib and Venetoclax (VEN) + Azacitidine (AZA) · Experimental
- Arm B: Placebo and Venetoclax (VEN) + Azacitidine (AZA) · Placebo comparator
- Enrollment
- 600 (estimated)
- Primary outcomes
- Percentage of Participants who Achieve Complete Remission (CR)
- Overall Survival (OS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Jun 4, 2025
- Primary completion
- Jun 22, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06852222 · updated Sep 25, 2026